Published in Blood on July 01, 1999
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 4.52
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood (2009) 1.95
Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med (2002) 1.68
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood (2012) 1.67
Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol (2013) 1.59
IPD--the Immuno Polymorphism Database. Nucleic Acids Res (2009) 1.58
Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 1.56
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood (2007) 1.55
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol (2013) 1.53
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res (2010) 1.51
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood (2010) 1.49
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 1.44
Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol (2007) 1.43
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood (2011) 1.41
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2009) 1.41
IPD--the Immuno Polymorphism Database. Nucleic Acids Res (2012) 1.41
The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood (2007) 1.39
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol (2008) 1.32
Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 1.27
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.26
Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation (2010) 1.25
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2010) 1.22
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol (2007) 1.20
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol (2014) 1.20
What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant (2009) 1.16
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.14
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica (2012) 1.14
Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol (2010) 1.13
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther (2007) 1.13
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant (2008) 1.13
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica (2014) 1.12
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood (2014) 1.09
Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol (2008) 1.05
The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.04
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2010) 1.03
Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med (2009) 1.02
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother (2011) 0.98
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood (2005) 0.98
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia (2009) 0.97
NK cells in therapy of cancer. Crit Rev Oncog (2014) 0.96
Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol (2014) 0.95
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion (2012) 0.94
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol (2012) 0.93
Natural killer cell-based therapies. F1000 Med Rep (2011) 0.93
Review: Immunogenetics of human placentation. Placenta (2011) 0.92
Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant (2008) 0.92
Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One (2011) 0.91
Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother (2008) 0.91
Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer (2012) 0.91
Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation (2008) 0.91
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica (2014) 0.91
Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol (2008) 0.91
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res (2010) 0.90
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol (2009) 0.88
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia (2014) 0.86
Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy. Biol Blood Marrow Transplant (2009) 0.86
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One (2009) 0.85
Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease. Sci Transl Med (2014) 0.85
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.85
High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. Haematologica (2016) 0.85
Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne) (2016) 0.84
Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol (2002) 0.84
Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front Immunol (2013) 0.83
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int (2016) 0.83
Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.83
Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol (2008) 0.82
Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. Oncotarget (2016) 0.82
Loss of NK stimulatory capacity by plasmacytoid and monocyte-derived DC but not myeloid DC in HIV-1 infected patients. PLoS One (2011) 0.82
Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. Springer Semin Immunopathol (2004) 0.82
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant (2013) 0.81
Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant (2013) 0.81
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition. Immunogenetics (2017) 0.80
The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). J Clin Immunol (2006) 0.80
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica (2015) 0.80
Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy. Front Immunol (2015) 0.80
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Vet Comp Oncol (2007) 0.79
Donor major histocompatibility complex class I expression determines the outcome of prenatal transplantation. J Pediatr Surg (2008) 0.79
Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Adv Hematol (2016) 0.79
Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One (2013) 0.79
"No donor"? Consider a haploidentical transplant. Blood Rev (2014) 0.78
Lymphoid reconstruction and vaccines. Biol Blood Marrow Transplant (2007) 0.78
Overview of T-cell depletion in haploidentical stem cell transplantation. Blood Transfus (2012) 0.78
Cognate HLA absence in trans diminishes human NK cell education. J Clin Invest (2016) 0.78
MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production. Am J Hematol (2015) 0.78
Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant (2015) 0.78
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med (1998) 5.71
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med (1991) 3.03
Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia (2000) 2.84
Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A (1999) 2.76
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood (1995) 2.67
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 2.65
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 2.38
Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol (2003) 2.35
Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol (2001) 2.16
Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia (1999) 2.16
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 2.02
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00
The EBMT activity survey: 1990-2010. Bone Marrow Transplant (2012) 1.96
Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal and pathological human tissues. J Immunol (1989) 1.89
Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood (2001) 1.88
Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer (2002) 1.67
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia (2005) 1.67
Monitoring levels of preservative sensitivity in Europe. A 10-year overview (1991-2000). Contact Dermatitis (2002) 1.63
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
Audiologic abnormalities in cases of vitiligo. J Am Acad Dermatol (1987) 1.59
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Nail changes in lichen planus may resemble those of yellow nail syndrome. Br J Dermatol (2000) 1.50
Multiple keratoacanthoma in discoid lupus erythematosus. J Am Acad Dermatol (1989) 1.46
Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol (2003) 1.44
Onychoblastoma (hamartoma of the nail unit): a new entity? Br J Dermatol (2005) 1.43
Percutaneous transluminal coronary angioplasty procedure is associated to a decrease in transforming growth factor beta 1 levels. Thromb Haemost (1999) 1.42
Does pain confound interpretation of neuropsychological test results? NeuroRehabilitation (2001) 1.41
Congenital hypertrophy of the lateral nail folds of the hallux: clinical features and follow-up of seven cases. Pediatr Dermatol (2001) 1.40
Thyroid function in systemic sclerosis. J Endocrinol Invest (1991) 1.38
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol (1996) 1.38
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia (2007) 1.36
Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant (2013) 1.34
A new classification of onychomycosis. Br J Dermatol (1998) 1.33
Periungual and subungual pyogenic granuloma. Br J Dermatol (2010) 1.27
Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol (1997) 1.27
Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood (1995) 1.26
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia (1999) 1.26
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1996) 1.24
Ferrichrome transport in inner membrane vesicles of Escherichia coli K12. J Biol Chem (1978) 1.24
Contact dermatitis in hairdressers: the Italian experience. Gruppo Italiano Ricerca Dermatiti da Contatto e Ambientali. Contact Dermatitis (1992) 1.24
Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology (1990) 1.24
Gallstone prevalence and gallbladder volume in children and adolescents: an epidemiological ultrasonographic survey and relationship to body mass index. Am J Gastroenterol (1989) 1.23
Histological and immunohistological analysis of human lymphomas. Crit Rev Oncol Hematol (1989) 1.22
Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 1.20
Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol (1994) 1.19
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med (1993) 1.19
Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother (2000) 1.19
Hair casts are a dermoscopic clue for the diagnosis of traction alopecia. Br J Dermatol (2010) 1.17
Chronic pain and neuropsychological functioning. Neuropsychol Rev (2000) 1.17
Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant (2001) 1.16
What causes alopecia areata? Exp Dermatol (2013) 1.14
Anxiety, information, interpersonal impacts, and adjustment to a stressful health care situation. J Pers Soc Psychol (1983) 1.14
Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood (1993) 1.13
Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies. Hum Pathol (1990) 1.13
Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood (1997) 1.12
Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant (2001) 1.12
Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol (2001) 1.11
The use of the polymerase chain reaction for the detection of minimal residual malignant disease. Blood (1991) 1.11
The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol (1999) 1.09
Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut (1997) 1.09
Brittle nails. J Cosmet Dermatol (2004) 1.09
Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol (1996) 1.08
Contact dermatitis in hairdressers' clients. Contact Dermatitis (1992) 1.08
Analysis of T cells bearing different isotypic forms of the gamma/delta T cell receptor in patients with systemic autoimmune diseases. J Rheumatol (1991) 1.07
Celiac disease and alopecia areata: report of a new association. Gastroenterology (1995) 1.06
Immunohistological analysis of human bone marrow trephine biopsies using monoclonal antibodies. Br J Haematol (1984) 1.06
Metastatic carcinoma to the terminal phalanx of the big toe: report of two cases and review of the literature. J Am Acad Dermatol (1994) 1.05
Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc (1996) 1.05
Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol (1997) 1.05
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol (1994) 1.05
Drug-induced nail disorders: incidence, management and prognosis. Drug Saf (1999) 1.04
Contribution to the knowledge of dermatophytic invasion of hair. An investigation with the scanning electron microscope. J Invest Dermatol (1970) 1.04
Functional analysis of cloned germinal center CD4+ cells with natural killer cell-related features. Divergence from typical T helper cells. J Immunol (1986) 1.04
An immunofluorescence analysis of the ontogeny of myeloid, T, and B lineage cells in mouse hemopoietic tissues. J Immunol (1984) 1.03
S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol (2010) 1.03
Serological screening for coeliac disease in vitiligo and alopecia areata. Br J Dermatol (1997) 1.03
Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies. J Immunol Methods (1986) 1.03
Energy-transducing H+-ATPase of Escherichia coli. Reconstitution of proton translocation activity of the intrinsic membrane sector. J Biol Chem (1980) 1.02
Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia (2007) 1.01
Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol (1999) 1.01
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2000) 1.01
Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol (2000) 1.01
The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatology (1995) 1.01
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood (1996) 1.00
Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood (1992) 0.99
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant (2000) 0.99
How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. Br J Dermatol (2009) 0.99
Expression of lymphoid-associated antigens on Hodgkin's and Reed-Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies. Histopathology (1987) 0.99